Bristol-Myers Squibb Company logo BMY - Bristol-Myers Squibb Company

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 19
HOLD 20
SELL 2
STRONG
SELL
0
| PRICE TARGET: $62.60 DETAILS
HIGH: $75.00
LOW: $40.00
MEDIAN: $60.00
CONSENSUS: $62.60
UPSIDE: 10.41%

About Bristol-Myers Squibb Company (https://www.bms.com)

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Key Executives

NAME TITLE DOB SALARY
Christopher S. Boerner Chief Executive Officer & Chairman 1971 $5,818,520 USD
David V. Elkins Executive Vice President & Chief Financial Officer 1968 $3,196,077 USD
Adam Lenkowsky Executive Vice President & Chief Commercialization Officer 1972 $3,176,492 USD
Greg Meyers Executive Vice President and Chief Digital & Technology Officer 1973 $2,972,005 USD
Karin Shanahan Executive Vice President, Chief Supply Chain & Operations Officer 1965 $2,420,673 USD
Cristian Massacesi Executive Vice President, Chief Medical Officer & Head of Development 1969 $2,218,956 USD
Ahn Amanda Poole Executive Vice President & Chief People Officer 1975
Cari Gallman Executive Vice President, General Counsel & Chief Policy Officer 1980
Charles E. Triano SVP & Head of Investor Relations
Joseph J. Eiden Jr. Head of Medical Affairs 1949

Company Peers

Peer analysis pending, check back in 1-2 minutes.